The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Genome-Informed Targeted Therapy for Osteosarcoma
Open accessAbstract
Osteosarcoma is a highly aggressive cancer for which treatment has remained essentially unchanged for more than 30 years. Osteosarcoma is characterized by widespread and recurrent somatic copy-number alterations (SCNA) and structural rearrangements. In contrast, few recurrent point mutations in protein-coding genes have been identified, suggesting that genes within SCNAs are key oncogenic drivers in this disease. SCNAs and structural rearrangements are highly heterogeneous across osteosarcoma cases, suggesting the need for a genome-informed approach to targeted therapy. To identify patient-specific candidate drivers, we used a simple heuristic based on degree and rank order of copy-number amplification (identified by whole-genome sequencing) and changes in gene expression as identified by RNA sequencing. Using patient-derived tumor xenografts, we demonstrate that targeting of patient-specific SCNAs leads to significant decrease in tumor burden, providing a road map for genome-informed treatment of osteosarcoma. Significance: Osteosarcoma is treated with a chemotherapy regimen established 30 years ago. Although osteosarcoma is genomically complex, we hypothesized that tumor-specific dependencies could be identified within SCNAs. Using patient-derived tumor xenografts, we found a high degree of response for “genome-matched” therapies, demonstrating the utility of a targeted genome-informed approach. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the paitients with metastatic disease either at diagnosis or at the time of recurrence portends a dismal prognosis with 5-year survival of only 20-30% [8].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“This genomic complexity has long been interpreted as a sign of chromosomal instability but emerging data suggest that the mechanisms triggering complexity are active early in the process of malignant transformation 35,37 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“These rearrangements give rise to genome-wide copy number alterations, usually dominated by copy number loss, including of PTEN and CDKN2A/B, but with recurrent amplifications of MYC, VEGFA and CCNE1 (ref.35 ).”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Of note, the resulting complex genomes are subsequently maintained with some fidelity, even from diagnosis to relapse 35,37 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Copy number amplifications of potentially targetable genes seemed to predict sensitivity to specific agents 35 ; however, subsequent work has shown that the picture is much more complicated 9 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Recurrent CDK4 alterations have been described in osteosarcoma 35 .”
From Osteosarcoma (2022) · cites this paper as [35]
In the citing paper
“Furthermore, current molecular research continues to classify osteosarcomas not by histological appearance via classical osteosarcoma pathological descriptions but by proteo-genomic drivers of disease that provide further insight into disease biology and may have both prognostic and therapeutic implications 35 .”
From Osteosarcoma (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEMPreprint
Li, H. (2013) · arXiv (Cornell University) · doi:10.48550/arxiv.1303.3997 · Cited by 10,154
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Landscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEMPreprint
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 5,155
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,926
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
DELLY: structural variant discovery by integrated paired-end and split-read analysis
Rausch, T., Zichner, T., Schlattl, A., Stütz, A. M., Beneš, V., & Korbel, J. O. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts378 · Cited by 2,438
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Emerging landscape of oncogenic signatures across human cancers
Ciriello, G., Miller, M. L., Aksoy, B. A., Şenbabaoğlu, Y., Schultz, N. D., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,401
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Goel, H. L., & Mercurio, A. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3627 · Cited by 1,258
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
Carmena, M., Wheelock, M., Funabiki, H., & Earnshaw, W. C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3474 · Cited by 934
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 930
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24320 · Cited by 791
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 672
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
Self-citationAnders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Targeting CDK4/6 in patients with cancer
Hamilton, E. P., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 495
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481
Bruna, A., Rueda, O. M., Greenwood, W., Batra, A. S., Callari, M., Batra, R. N., McNamara, K. L., Sandoval, J. L., Cassidy, J. W., Vidaković, A. T., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.041 · Cited by 442
DGIdb 2.0: mining clinically relevant drug–gene interactions
Wagner, A. H., Coffman, A. C., Ainscough, B. J., Spies, N. C., Skidmore, Z. L., Campbell, K. M., Krysiak, K., Pan, D., McMichael, J. F., Eldred, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1165 · Cited by 413
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I. A., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 410
Cancer genetics and genomics of human FOX family genes
Katoh, M., Igarashi, M., Fukuda, H., Nakagama, H., & Katoh, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.017 · Cited by 401
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Applewhite, A., Sun, M., & LaQuaglia, M. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 389
Wilkinson, R. W., Odedra, R., Heaton, S. P., Wedge, S. R., Keen, N., Crafter, C., Foster, J. R., Brady, M. C., Bigley, A. L., Brown, E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2979 · Cited by 358
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 345
DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Dickson, M. A., Schwartz, G. K., Keohan, M. L., D’Angelo, S. P., Gounder, M. M., Chi, P., Antonescu, C. R., Landa, J., Qin, L., Crago, A. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0264 · Cited by 327
Orthotopic patient-derived xenografts of paediatric solid tumours
Stewart, E., Federico, S. M., Chen, X., Shelat, A. A., Bradley, C., Gordon, B., Karlstrom, A., Twarog, N. R., Clay, M. R., Bahrami, A., et al. (2017) · Nature · doi:10.1038/nature23647 · Cited by 286
NGSUtils: a software suite for analyzing and manipulating next-generation sequencing datasets
Breese, M. R., & Liu, Y. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts731 · Cited by 278
Self-citationBehjati, S., Tarpey, P. S., Haase, K., Ye, H., Young, M. D., Alexandrov, L. B., Farndon, S. J., Collord, G., Wedge, D. C., Martincorena, I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15936 · Cited by 261
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaPreprint
Huang, C., Lujambio, A., Zuber, J. A., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T. M., Zhu, N., de Stanchina, E., Sawyers, C. L., et al. (2014) · Genes & Development · doi:10.1101/gad.244368.114 · Cited by 204
Pignochino, Y., Grignani, G., Cavalloni, G., Motta, M., Tapparo, M., Bruno, S., Bottos, A., Gammaitoni, L., Migliardi, G., Camussi, G., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-118 · Cited by 182
Pašić, I., Shlien, A., Durbin, A. D., Stavropoulos, D. J., Baskin, B., Ray, P. N., Novokmet, A., & Malkin, D. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1902 · Cited by 173
Patient‐derived xenografts for individualized care in advanced sarcoma
Stebbing, J., Paz, K., Schwartz, G. K., Wexler, L. H., Maki, R. G., Pollock, R. E., Morris, R., Cohen, R., Shankar, A., Blackman, G., et al. (2014) · Cancer · doi:10.1002/cncr.28696 · Cited by 157
Au‐Yeung, G., Lang, F., Azar, W. J., Mitchell, T. J., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C. M., Pearson, R. B., Mileshkin, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 147
Santo, L., Vallet, S., Hideshima, T., Cirstea, D. D., Ikeda, H., Pozzi, S., Patel, K. J., Okawa, Y., Görgün, G., Perrone, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.510 · Cited by 144
Kuijjer, M. L., Rydbeck, H., Kresse, S. H., Buddingh, E. P., Lid, A. H. B., Roelofs, H., Buerger, H., Myklebost, O., Hogendoorn, P. C. W., Meza‐Zepeda, L. A., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21956 · Cited by 137
Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Bayani, J., Zieleńska, M., Pandita, A., Al-Romaih, K. I., Karásková, J., Harrison, K. J., Bridge, J. A., Sorensen, P. H. B., Thorner, P. S., & Squire, J. A. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10132 · Cited by 127
Yang, J., Yang, D., Sun, Y. K., Sun, B., Wang, G., Trent, J. C., Araujo, D. M., Chen, K., & Zhang, W. (2011) · Cancer · doi:10.1002/cncr.26116 · Cited by 125
Baker, E. K., Taylor, S., Gupte, A., Sharp, P. P., Walia, M., Walsh, N. C., Zannettino, A. C. W., Chalk, A. M., Burns, C. J., & Walkley, C. R. (2015) · Scientific Reports · doi:10.1038/srep10120 · Cited by 123
Parent-specific copy number in paired tumor–normal studies using circular binary segmentation
Olshen, A. B., Bengtsson, H. L., Neuvial, P., Spellman, P. T., Olshen, R. A., & Seshan, V. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr329 · Cited by 122
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 108
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors
Freeman, S. S., Allen, S. W., Ganti, R., Wu, J., Ma, J., Su, X., Neale, G. A. M., Dome, J. S., Daw, N. C., & Khoury, J. D. (2008) · Cancer · doi:10.1002/cncr.23782 · Cited by 102
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Yang, L., Fang, D., Chen, H., Lu, Y.-Y., Dong, Z., Ding, H., Jing, Q., Su, S., & Huang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4600 · Cited by 100
Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions
Moretti, S., Pinzi, C., Spallanzani, A., Berti, E., Chiarugi, A., Mazzoli, S., Fabiani, M., Vallecchi, C., & Herlyn, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990420)84:2 · Cited by 98
Zhao, F., Siu, M. K. Y., Jiang, L., Tam, K. F., Ngan, H. Y. S., Le, X. F., Wong, O. G. W., Wong, E. S. Y., Gomes, A. R., Bella, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113478 · Cited by 88
Kim, A., Widemann, B. C., Krailo, M., Jayaprakash, N., Fox, E., Weigel, B. J., & Blaney, S. M. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25548 · Cited by 87
Jorge, S. E., Schulman, S., Freed, J. A., VanderLaan, P. A., Rangachari, D., Kobayashi, S. S., Huberman, M. S., & Costa, D. B. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.028 · Cited by 82
Fu, W., Ma, L., Chu, B., Wang, X., Bui, M. M., Gemmer, J. Y., Altiok, S., & Pledger, W. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0167 · Cited by 81
Chen, E. X., Hotte, S. J., Hirte, H. W., Siu, L. L., Lyons, J., Squires, M. S., Lovell, S., Turner, S., McIntosh, L., & Seymour, L. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.565 · Cited by 72
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Dolman, M. E. M., Poon, E., Ebus, M. E., den Hartog, I. J. M., van Noesel, C. J. M., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K. R., Sparidans, R. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0313 · Cited by 66
The genetic basis for inactivation of Wnt pathway in human osteosarcoma
Du, X., Yang, J., Yang, D., Tian, W., & Zhu, Z. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-450 · Cited by 62
Fletcher (2009) · International Journal of Oncology · doi:10.3892/ijo_00000390 · Cited by 62
Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
Fowler, T., Ghatak, P., Price, D. H., Conaway, R., Conaway, J. W., Chiang, C., Bradner, J. E., Shilatifard, A., & Roy, A. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087003 · Cited by 61
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
Lockwood, W. W., Stack, D., Morris, T., Grehan, D., O’Keane, C., Stewart, G. L., Cumiskey, J., Lam, W. L., Squire, J. A., Thomas, D. M., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.020 · Cited by 59
Establishment of a patient-derived orthotopic osteosarcoma mouse model
Blattmann, C., Thiemann, M., Stenzinger, A., Roth, E. K., Dittmar, A., Witt, H., Lehner, B., Renker, E. K., Jugold, M., Eichwald, V., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0497-x · Cited by 51
Subbiah, V., Wagner, M. J., McGuire, M. F., Sarwari, N., Devarajan, E., Lewis, V. O., Westin, S., Kato, S., Brown, R. E., & Anderson, P. M. (2015) · Oncotarget · doi:10.18632/oncotarget.5841 · Cited by 49
Goldstein, S. D., Hayashi, M., Albert, C. M., Jackson, K. W., & Loeb, D. M. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9738-x · Cited by 45
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
Tavanti, E., Sero, V., Vella, S., Fanelli, M., Michelacci, F., Landuzzi, L., Magagnoli, G., Versteeg, R., Picci, P., Hattinger, C. M., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.643 · Cited by 38
Both, J., Krijgsman, O., Bras, J., Schaap, G. R., Baas, F., Ylstra, B., & Hulsebos, T. J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115835 · Cited by 38
A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma
Coventon, J. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.07.001 · Cited by 35
Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics
Guilhamon, P., Butcher, L. M., Presneau, N., Wilson, G. A., Feber, A., Paul, D. S., Schütte, M., Haybaeck, J., Keilholz, U., Hoffman, J., et al. (2014) · Genome Medicine · doi:10.1186/s13073-014-0116-0 · Cited by 27
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma
Bishop, M. W., & Janeway, K. A. (2016) · F1000Research · doi:10.12688/f1000research.8228.1 · Cited by 26
Reed, D. R., Mascarenhas, L., Manning, K., Hale, G. A., Goldberg, J., Gill, J. B., Sandler, E. S., Isakoff, M. S., Smith, T., Caracciolo, J. T., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.598 · Cited by 16
Flagged first, then by citations
1 of the 78 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20059-6 · Cited by 672
New Horizons in the Treatment of Osteosarcoma
Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K. J., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. L. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 343
Metadata
- Authors
- Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., Hazard, F. K., Spunt, S. L., Marina, N., Kim, G. E., Cho, S.-J., Avedian, R. S., Mohler, D. G., Kim, M.-O., DuBois, S. G., Hawkins, D. S., & Sweet-Cordero, E. A.
- Affiliations
- University of California, San Francisco (US)
- 1Division of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, California.
- Stanford Medicine (US)
- Harvard University (US)
- Seattle Children's Hospital (US)
- ORCID
- Venue
- Cancer Discovery
- Published
- 2019-01-01
- Volume
- 9
- Issue
- 1
- Pages
- 46-63
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7134333
- OpenAlex
- W2892650455
- Cited by
- 452
- References
- 78
- Citations by year
- 2026: 48 · 2025: 59 · 2024: 67 · 2023: 84 · 2022: 63 · 2021: 63 · 2020: 52 · 2019: 14
- FWCI
- 24.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HHS | National Institutes of Health (NIH) (S10OD018220, P30CA082103, 2T32OD011121-11, R25 CA180993-02)
- Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels (Hope On Wheels)
- Stanford University School of Medicine (Stanford School of Medicine, Stanford University) (Morgridge Scholar Grant)
- St. Baldrick's Foundation (Team Clarkie)
- CureSearch for Children's Cancer
- Sarcoma Foundation of America (SFA)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- osteosarcoma, somatic copy number alterations, structural rearrangement, targeted therapy, patient-derived xenografts, copy number amplification, gene expression changes, oncogenic drivers
- MeSH terms
- Whole Genome Sequencing, Animals, Bone Neoplasms, Humans, Osteosarcoma, Sequence Analysis, RNA, Xenograft Model Antitumor Assays, Genomics, Mice, Genomic Structural Variation, DNA Copy Number Variations, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
